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Obesity is a global public health problem that is linked with morbidity, mortality, and func-
tional limitations and has limited options for sustained interventions. Novel targets for pre-
vention and intervention require further research into the pathogenesis of obesity. Consis-
tently, elevated markers of inflammation have been reported in association with obesity, but
their causes and consequences are not well understood. An emerging field of research has
investigated the association of infections and environmental pathogens with obesity, poten-
tial causes of low grade inflammation that may mediate obesity risk. In this study, we esti-
mate the possible association betweenToxoplasma gondii (T. gondii ) infection and obesity in
a sample of 999 psychiatrically healthy adults. Individuals with psychiatric conditions, includ-
ing personality disorders, were excluded because of the association between positive serol-
ogy to T. gondii and various forms of serious mental illness that have a strong association
with obesity. In our sample, individuals with positiveT. gondii serology had twice the odds
of being obese compared to seronegative individuals (p=0.01). Further, individuals who
were obese had significant higher T. gondii IgG titers compared to individuals who were
non-obese. LatentT. gondii infection is very common worldwide, so potential public health
interventions related to this parasite can have a high impact on associated health concerns.
Keywords: obesity, body weight,Toxoplasma gondii, parasitic infection, inflammation
INTRODUCTION
Approximately 57% of the world’s adult population is projected
to be obese or overweight by 2030 (1), highlighting the press-
ing need for research on obesity pathogenesis to identify novel
targets for intervention. Public perception is that lifestyle prac-
tices have “a lot to do” with causing obesity (2), and the Amer-
ican Heart Association emphasizes accurate tracking of diet and
activity for weight management (3). However, lifestyle interven-
tion often results in modest and unsustained weight loss (4).
Emerging research on etiology of obesity has investigated the
potential role of environmental infections, a concept referred to
as “infectobesity” (5, 6), as well as gut microbiota (7) in obe-
sity pathogenesis. If the suspected role of infection in obesity is
confirmed, then individuals with obesity of this type might be
treated by specifically addressing underlying causes rather than
relying on a standard diet and activity intervention (8). More-
over, novel prevention strategies may be developed that may
supplement the current, relatively stagnant, diet, and activity
recommendations.
The first report of virus-induced obesity in an animal model
was reported by Lyons et al. (9) after exposing mice to canine
distemper virus. Since that time, several viruses have been shown
to cause obesity in animal models (6). Herpes simplex viruses 1
and 2, gut microflora,Helicobacter pyloris, Selenomonas noxia, and
Chlamydophila pneumonia have been studied for possible associ-
ation of infection with obesity, with adenovirus 36 (Ad36) being
the most studied in humans (10), although a causal role is unclear
(11). Yamada et al. (12) reported an association of Ad36 infec-
tion with obesity risk and weight gain, but not with abdominal
obesity (i.e., increased waist circumference), suggesting that Ad36
infection is preferentially associated with accumulation of subcu-
taneous fat as opposed to visceral fat. Interestingly, but consistent
with the concept that proliferation of subcutaneous fat may avert
the storage of metabolically harmful “ectopic fat” in the liver and
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omentum, insulin sensitivity and glycemic control was shown to
be superior in individuals seropositive for Ad36 compared with
seronegative individuals (13).
Possible mechanisms for infection-induced obesity may involve
a peripheral effect on fat cell differentiation and storage or a central
effect on appetite (6). Adipose tissue expansion may occur during
acute infection only or possibly sustained during latent or chronic
illness (14).
An understudied pathogen of potential interest in obesity
research is the protozoan parasite Toxoplasma gondii (T. gondii).
T. gondii is a parasite common in both developed and develop-
ing countries (15), infecting approximately 30% of the popula-
tion worldwide (16). Its life cycle involves distinct developmental
stages. It takes the form of a rapidly replicating tachyzoite dur-
ing acute infection and progresses in an immunocompetent host
to a slower, relatively dormant growing bradyzoite within tissue
cysts. Sexual reproduction or oocyst state can only be achieved if
the parasite is transmitted to a feline host (17). The most com-
mon cause of human infection is by ingestion of undercooked
meat or incomplete washing of contaminated vegetables, but can
also occur via accidental inoculation of tachyzoites, organ trans-
plantation, blood transfusion, or transplacental transmission from
infected mothers (18). Acute infection may cause minimal (e.g.,
lymphadenopathy) or no symptoms, and latent infection in an
immunocompetent individual is likely to become symptomatic
only under conditions of immunosuppression (15). Individuals
are not routinely screened for infection unless they are pregnant
or immunocompromised.
Experimentally, in rats, T. gondii infection was associated with
significant weight gain after 30 days of inoculation followed by
weight loss over the next 60 days (19). The authors hypothesized
that weight gain may have been due to direct central effects, i.e.,
behavioral changes (e.g., increased food intake) associated with
T. gondii cysts in the brain and/or indicated central effects, e.g.,
altered hypothalamic function (e.g., appetite regulation) caused
by peripheral tissue inflammation. Weight related effects of T.
gondii infection may be influenced by strain. In another animal
study, two different strains of T. gondii had opposite effects on
body weight (20).
The only previous study investigating the possible association
betweenT. gondii and obesity in humans reported negative results.
Thjodleifsson et al. (21) measuredT. gondii IgG antibodies among
individuals participating in the European Community Health Sur-
vey I. There was no significant difference in presence of antibodies
among individuals who were overweight (BMI ≥25 kg/m2) com-
pared to those who were not overweight. A possible factors which
may have influenced the lack of association was the exclusion
of adults >44 years old, since acquired toxoplasmosis increases
with age.
In our study, we investigated the possible association between
obesity and toxoplasmosis in a sample of adults (including individ-
uals 18–80 years), in a country (Germany) with a high seropreva-
lence rate of T. gondii infection. We hypothesized that positive T.
gondii serology will be more common among individuals who are
obese compared to those who are non-obese, and that antibody
titers will be higher for the obese individuals. We also tested for
an association between obesity and seropositivity of two other
common latent infections that often co-occur with toxoplasmosis
(CMV and HSV1) to see if the association is specific to T. gondii.
MATERIALS AND METHODS
PARTICIPANTS
Detailed recruitment methodology is described in Serretti (22).
Adult male and female individuals ages 18–80 years old were
randomly selected from the Munich, city registry in Germany and
invited by mail to participate. Study recruitment began in 1998.
Those who responded were screened by phone to obtain medical
and psychiatric histories. Individuals whose phone screening was
negative were invited to complete a clinic visit where they under-
went the Structured Clinical Interview for DSM-IV [SCID I and
SCID II; (23–25)] to validate the absence of any lifetime history
of mental illness and personality disorders. The participants also
underwent a neurological examination to exclude the presence of
any current CNS impairment and the Family History Assessment
Module (26) was administered to rule out the presence of psychi-
atric disorders in their first-degree relatives. The Mini Mental State
Examination was used to rule out possible cognitive impairment
in those older than 60 years. Weight and height was obtained by
self-report. Waist circumference was measured at the study visit.
Education level, graded according to a three-level variable (1 for
secondary school; 2 for junior high school, and 3 for general quali-
fication for university entrance) was used to define socioeconomic
status.
The study was conducted in accordance with the ethical stan-
dards of the 1964 Declaration of Helsinki and with approval of
the local ethics committee in Germany. Written informed consent
was obtained from all subjects.
T. GONDII SEROLOGICAL ANALYSIS
Solid phase enzyme immunoassay method was used to test for IgG
antibodies to T. gondii as previously described (27). This proce-
dure involved exposure of diluted serum to antigens embedded
on the wells of microtiter plates. Antibody binding was quantified
by reaction labeled anti-human IgG with the enzyme substrate.
Quantitative measurement of antibodies (i.e., serointensity) was
based on the ratio of the optical density of the blood sample and a
standard containing 10 international units of anti-T. gondii anti-
body. Seropositivity was defined as a T. gondii IgG titer≥0.8 (27).
The lab analysis was done at Dr. Robert Yolken’s lab at Johns Hop-
kins University supported by Stanley Medical Research Institute.
The technician was blind to the study hypothesis.
Data analysis plan
Descriptive statistics included proportions for categorical vari-
ables and means, standard deviations for continuous variables;
continuous distributions were inspected for outliers and skew-
ing. Proportions were compared by chi-squared tests; means were
compared by t -tests or one-way ANOVA with LSD post hoc com-
parisons. Logistic regression models were built to assess relative
odds for obesity comparing T. gondii seropositives with seroneg-
atives. Linear regression models were built to estimate adjusted
mean T. gondii serum IgG titers by waist circumference. Age, sex,
and education were included in models if they changed coefficients
by approximately 10% or more, or were significantly associated
with the outcome.
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RESULTS
The continuous BMI variable was used to generate three strata
of obesity categories – obese (BMI >30 kg/m2), overweight (BMI
≤30 or ≥25), and non-obese/overweight (BMI <25 kg/m2). The
weight and height given by one participant indicated a BMI of
>65, suggesting a rare, genetic cause of obesity. This individual was
excluded from all further analyses and tables. Demographics of the
participant sample and BMI distribution byT. gondii seropositivity
status (positive or negative) are presented in Table 1. As expected,
there was a significantly increasing trend of seropositivity with
age (i.e., increased time for possible environmental exposure).
Gender was not associated with obesity. Male and female gen-
der were almost evenly distributed in the entire sample and in
both the T. gondii positive and negative groups so gender was not
adjusted in the analysis. Individuals with higher levels of educa-
tion had lower odds of obesity compared with those with lower
education background. About 7.4% of the sample was obese (BMI
≥30 kg/m2).
Individuals who were positive for T. gondii IgG had approxi-
mately twice the odds of being obese compared to seronegative
individuals, adjusting for age (p= 0.01) (see Table 2). Further,
individuals who were obese had significantly higher levels of IgG
than individuals who were overweight or normal (p= 0.01). There
was no significant difference in IgG titers for individuals who were
overweight compared to normal weight. Gender and education
(as a surrogate for socioeconomic status) were also assessed for
confounding; when entered into the models there was no change
in the effects of BMI. Neither CMV nor HSV1 seropositivity was
significantly associated with obesity after adjusting for age and
education.
DISCUSSION
To our knowledge, this is the first study to identify an associa-
tion between T. gondii and obesity among individuals carefully
screened for mental illness, including personality disorders. Men-
tal illness is an important confounding variable, since obesity
rates are higher among individuals with serious mental illness,
and latent T. gondii infection has been previously associated with
schizophrenia (28), bipolar disorder (29), and personality disorder
(29). Screening for mental illness, as well as self-selection bias, may
have resulted in a relatively lean sample, as only less than 10% of
individuals in the study were obese. In contrast, a German study
with a large adult sample from a primary care setting that did not
screen for mental illness, approximately 24% of males and 23% of
women were obese (30).
Because this is an association study, we are unable to determine
if there is a causal relationship betweenT. gondii seropositivity and
obesity. However, evidence from animal studies indicates possible
connections between parasite survival and obesity risk. Parasites
may alter host appetite regulation to increase nutrient intake. For
example, infection with Taenia taeniaeformis is associated with
lower levels of leptin (31). Leptin is a peptide appetite hormone
that signals satiety so lower levels would stimulate food intake.
Parasites may also indirectly increase appetite through behav-
ioral changes. T. gondii brain cysts have greater distribution in
the amygdala and nucleus accumbens, brain regions that may be
primarily targeted to influence fear signaling to promote survival
Table 1 | Demographics of study sample.







N (%) N (%) N (%)
Sex
Male 255 (51.2) 235 (46.9) 490 (49.1) 0.17
Female 243 (48.8) 266 (53.1) 509 (51.0)
Education level
1 153 (30.7) 92 (18.4) 245 (24.6) <0.0001
2 155 (31.1) 147 (29.4) 302 (30.3)
3 190 (38.2) 261 (52.2) 451 (45.2)
Age (quartiles)
<40 years 59 (11.9) 179 (35.7) 238 (23.8) <0.0001
40 to <60 122 (24.5) 141 (28.1) 263 (26.3)
60 to <67 130 (26.1) 97 (19.4) 227 (22.7)
≥67 187 (37.6) 84 (16.8) 271 (27.1)
BMI
Normal <25 265 (53.3) 310 (62.1) 575 (57.7) 0.0001
Overweight <30 179 (36.0) 168 (33.7) 347 (34.8)
Obese 30+ 53 (10.7) 21 (4.2) 74 (7.4)
One participant with BMI >65 was omitted as an outlier.
Table 2 | Age-adjusted odds ratios for obesity (BMI ≥30) compared to
overweight and normal participants combined, from logistic
regression analysis.
Obese vs. non-obese
OR 95% CI p Value
T. gondii positive vs. negative 1.97 1.15, 3.39 0.01
Age (quartiles)
<40 years 1.00 – ref
40 to <60 vs. <40 2.40 0.86, 6.70 0.10
60 to <67 vs. <40 3.43 1.24, 9.52 0.02
≥67 vs. <40 3.35 1.22, 9.20 0.02
Sex male vs. female 0.81 0.49, 1.33 0.40
Education
1 1.00 – ref
2 vs. 1 0.89 0.51, 1.57 0.70
3 vs. 1 0.39 0.20, 0.75 0.005
1= secondary education; 2= junior high school education; 3=university equiva-
lent.
(i.e., reduced vigilance may make infected rodents more suscep-
tible to predator cats who are the definitive host for replication)
and these regions also influences reward driven behavior (e.g.,
eating related behaviors) (32). T. gondii may also influence moti-
vation and reward driven behaviors through altered dopamine
pathways. Animal models indicate that T. gondii influences both
dopamine release and availability of the rate limiting enzyme in
dopamine synthesis, and dopamine antagonists (i.e., antipsychotic
medications) can block behavior changes in T. gondii infected rats
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(32). Thus, parasite induced host behavioral changes that may be
driven by survival needs may have inadvertent effects on eating
patterns that promote obesity. Parasites also may interfere with
host lipid metabolism. T. gondii “co-opts” some aspects of host
lipid metabolism, specifically tachyzoite acquisition of cholesterol
occurs through host cell endocytosis and the low density lipopro-
tein pathway (33). Thus, parasitic infection may have metabolic
effects beyond weight gain.
Toxoplasma gondii may also influence obesity risk through
alterations in inflammatory pathways. T cells play a major role
in T. gondii resistance, with mouse models demonstrating a strong
Th1 immune response to maintain the dormant bradyzoite stage
(34). Th1 immune response is maintained to promote long-lasting
immunity (35). Obesity has been previously referred to as “a state
of chronic inflammation” (36). In animal studies, mice with diet
induced obesity have more T cells in adipose tissue compared to
lean control mice (37), and diet controlled weight loss is associated
with reduced adipose tissue inflammation (38). Chronic inflam-
mation has been implicated in development of insulin resistance
and other metabolic abnormalities (39) and is associated with
reduced metabolic rate (40). Thus, the chronic, pro-inflammatory
state induced by latent T. gondii infection may either precipitate
(in non-obese individuals), perpetuate, or exacerbate (in obese
people) the inflammation related weight gain. In contrast, cer-
tain intestinal parasitic infections with nematodes induce a Th2-
polarized immune response and are associated with weight loss
(41), suggesting the possible association between body habitus
and pathogen is specific to the type of immune response and the
specific infectious agent. Of note, we did not find an association
between obesity and HSV or CMV1 seropositivity.
The association between T. gondii and obesity, if replicated, has
important public health significance because of the high preva-
lence of T. gondii worldwide. The CDC has prioritized T. gondii
as one of the top “Five Neglected Parasitic Infections” based on
its high prevalence in the US, severity of illness, and potential
for prevention (http://www.cdc.gov/parasites/npi.html; accessed
9-25-2013). Food-borne infections have continued to increase
in recent years, with increased consumer preference for exotic
and global food sources and public demand for free-range live-
stock, which drives greater exposure to environmental soil spread
pathogens (42). Possible public health interventions to reduce
T. gondii infection include vaccine development (43), interven-
tions (44), as well as efforts to reduce unsafe food handling
processes.
LIMITATIONS
The cross sectional nature of the study does not allow us to inves-
tigate possible causal relationships between T. gondii and obesity,
including a possible reverse causality (i.e., obesity promoting the
risk of T. gondii infection) or shared causality (i.e., a common fac-
tor causing both obesity and T. gondii infection). However, this
association, if replicated, supports the need for further research
to investigate the direction (i.e., does obesity increase risk of
latent infection or vice versa) and mechanisms that that drive this
relationship. Interventions that target host lipid metabolism, for
example, have been suggested as a novel intervention target for
T. gondii infection since this pathway is important for parasite
survival. (33) Such interventions may have the advantage of both
reducing risk of infection and promoting metabolic health.
Another limitation of the study is that weight (to determine
BMI) was provided by self-report. Interestingly, the Survey of
Health, Aging, and Retirement in Europe 2004 (SHARE) study
that interviewed individuals >50 years old from over 10 Euro-
pean countries indicated that Germans tended to “under-rate”
their health on self-report forms compared to respondents from
other countries (45), and in another European study with a large
primary care sample indicates that estimate BMI varied from true
measure by only+0.19 for men and+0.17 for women, suggesting
that self-report may be adequate for monitoring national obesity
prevalence (46).
CONCLUSION
This study identified a positive relationship between T. gondii
seropositivity and obesity in a relatively large sample carefully
screened for mental illness. Future studies are needed to exam-
ine the relationship between obesity and T. gondii titers over time
to investigate possible causality and persistence of this associa-
tion over time. Research is also needed to further assess possible
association between T. gondii and other metabolic parameters.
Serotyping could help determine if metabolic effects in humans
differ with different strains of pathogen. T. gondii latent infec-
tion may turn out to have excellent potential as a target for
public health interventions because of the high prevalence of
this condition, in both developed and underdeveloped coun-
tries, and the possibility of identifying novel targets for obesity
interventions.
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